OPTICO-LM: Comparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT

Sponsor
University Hospital Inselspital, Berne (Other)
Overall Status
Recruiting
CT.gov ID
NCT03820492
Collaborator
(none)
104
13
1
55.1
8
0.1

Study Details

Study Description

Brief Summary

Significant left main (LM) stenosis is associated with a poor prognosis, therefore, adequate judgement of the prognostic significance of LM stenosis is essential to improve patients' prognosis. Recently, fractional flow reserve (FFR) has become widespread practice and carries a Class Ia recommendation to assess functional significance of intermediate coronary stenosis in patients with stable angina. Intravascular ultrasound (IVUS)-derived minimum lumen area (MLA) represents an accurate measure to determine LM significance as shown in multiple studies, while optical coherence tomography (OCT) ,which is a novel intracoronary imaging method with a greater spatial resolution (15μm vs. 100μm), faster image acquisition and facilitated image interpretation, OCT derived-MLA has never been validated against FFR and accordingly, it is not mentioned in the current guidelines for myocardial revascularization. Coronary computed tomography angiography (CTA) has emerged as a noninvasive alternative of coronary angiography with its excellent negative predictive value, while the positive predictive value of CTA is limited. Computational fluid dynamics is an emerging method that enables prediction of blood flow in coronary arteries and calculation of FFR from computed tomography (FFRCT) noninvasively. Noninvasive and accurate assessment of functional significance would bring a great benefit for patients with LM stenosis, however, there are no data to evaluate the diagnostic accuracy of FFRCT for LM stenosis in comparison with FFR and minimal lumen area derived by OCT.

This study will investigate the optimal OCT-derived MLA cut-off point and the diagnostic performance of FFRCT for intermediate LM stenosis compared with FFR ≤0.8 as a reference standard.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: OCT, FFR, CTA and FFRCT
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
104 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Multimodality Assessment of Intermediate Left Main Stenosis: Comparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT
Actual Study Start Date :
May 28, 2019
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Other: Patient with left-main stenosis

Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT

Diagnostic Test: OCT, FFR, CTA and FFRCT
Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT

Outcome Measures

Primary Outcome Measures

  1. OCT vs. FFR [Measurement at Procedure/ Baseline Visit]

    - The area under the curve of OCT-derived MLA for FFR≤0.8

  2. OCT vs. FFR [Measurement at Procedure/ Baseline Visit]

    -The optimal cut-off point of OCT-derived MLA from receiver-operator characteristics curves for FFR≤0.8

  3. FFRCT vs. FFR [Measurement at Procedure/ Baseline Visit]

    Diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of FFRCT≤0.8 for FFR≤0.8

Secondary Outcome Measures

  1. OCT vs. FFR, RFR, resting Pd/Pa, FFRCT, QFR [Measurement at Procedure/ Baseline Visit]

    - The area under the curve and the optimal cut-off point of OCT-derived MLA from receiver-operator characteristics curves for FFR≤0.75, RFR≤0.89, resting Pd/Pa≤0.91, and FFRCT≤0.80 and QFR≤0.80

  2. OCT vs. FFR, RFR, resting Pd/Pa, FFRCT [Measurement at Procedure/ Baseline Visit]

    - Predictability of MLA, minimal lumen diameter, area stenosis, lesion length, eccentricity index, and plaque characteristics (plaque rupture, fibroatheroma, and calcification) for FFR ≤0.8, FFR≤0.75, RFR≤0.89, resting Pd/Pa≤0.91, and FFRCT≤0.80 and QFR≤0.80

  3. OCT vs. FFR, RFR, resting Pd/Pa, FFRCT [Measurement at Procedure/ Baseline Visit]

    - Correlation among OCT-derived MLA, FFR, RFR, resting Pd/Pa, and FFRCT and QFR

  4. OCT vs. CTA [Measurement at Procedure/ Baseline Visit]

    - Correlation between luminal diameter stenosis of CTA and OCT-derived MLA

  5. OCT vs. CTA [Measurement at Procedure/ Baseline Visit]

    - Diagnostic accuracy of plaque characteristics with presumed high risk characteristics including napkin ring sign, low attenuation plaque (<30HU), positive remodelling (remodelling index >1.1), and spotty calcium (<3mm) for thin and thick cap fibroatheroma by OCT.

  6. Clinical endpoint at 1 year [12 Month]

    Death

  7. Clinical endpoint at 1 year [12 Month]

    Myocardial infarction

  8. Clinical endpoint at 1 year [12 Month]

    Target vessel myocardial infarction

  9. Clinical endpoint at 1 year [12 Month]

    Target lesion revascularization

  10. Clinical endpoint at 1 year [12 Month]

    Target vessel revascularization

  11. Clinical endpoint at 1 year [12 Month]

    Any revascularization

  12. Clinical endpoint at 1 year [12 Month]

    Stent thrombosis

  13. Clinical endpoint at 1 year [12 Month]

    Stroke and transient ischemic attack

  14. Clinical endpoint at 1 year [12 Month]

    Acute renal failure

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Unprotected LM lesion [midshaft, and distal bifurcation (Medina 1,1,1 or 1,1,0 or 1,0,1 or 1,0,0)] of 30% to 80% angiographic diameter stenosis (DS) on visual estimation or equivocal disease by angiography.

  • Age ≥18 years.

  • Ability to give preliminary oral consent witnessed by an independent physician or sign written informed consent prior to any study-specific procedures.

Exclusion Criteria:
  • Significant distal lesions (>50% angiographic DS on visual estimation within the left anterior descending artery [LAD] or left circumflex artery [LCX], except for ostium of LAD or LCX or diseased side branch [e.g. diagonal branch, obtuse marginal branch])

  • Ostial LM disease.

  • Acute coronary syndrome (ACS) (non-ST-elevation ACS and ST-elevation MI).

  • LM In-stent restenosis.

  • Previous coronary stenting of the left coronary system.

  • Chronic total occlusion.

  • Previous coronary artery bypass graft.

  • Previous MI related to the left coronary artery.

  • Occurrence of ventricularization or hypotension during engagement of the LM ostial lesion.

  • The presence of hemodynamic instability.

  • Known renal insufficiency (serum creatinine >1.5mg/dL or receiving dialysis).

  • Female of childbearing potential (age <50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy.

  • Life expectancy less than 1 year.

  • Contraindication or known allergy against protocol-required medications including heparin, iodinated contrast, β-blocker, nitroglycerin, and adenosine.

  • Body mass index >35kg/m2.

  • Complex congenital heart disease other than anomalous coronary origins alone.

  • Ventricular septal defect.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Hospitalier Universitaire de Clermont-Ferrand Clermont-Ferrand France 63000
2 Institute Mutualiste Montsouris Paris France 75014
3 Centre Cardiologique du Nord Saint-Denis France 75014
4 Universitätsklinikum Giessen Justus-Liebig Universität Gießen Hesse Germany 35392
5 Friedrich Alexander Universität (FAU) , Medizinische Klinik 2 , Kardiologie und Angiologie Erlangen Germany 91054
6 Ageo Central General Hospital Ageo Japan 362-8588
7 Gifu heart center Gifu Japan 500-8384
8 Department of Cardiovascular Medicine Shinshu University School of Medicine Nagano Japan 390-8621
9 Kansai Medical University, Osaka Japan 573-1010
10 Medical Corporation Ouyuukai Tokorozawa Heart Center Saitama Japan 359-1142
11 Sapporo Higashi Tokushukai Hospital Sapporo Japan 065-0033
12 Inselspital Bern Switzerland 3010
13 CHUV Lausanne Switzerland 1011

Sponsors and Collaborators

  • University Hospital Inselspital, Berne

Investigators

  • Principal Investigator: Lorenz Raeber, Prof. MD PhD, Inselspital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University Hospital Inselspital, Berne
ClinicalTrials.gov Identifier:
NCT03820492
Other Study ID Numbers:
  • OPTICO-LM
First Posted:
Jan 29, 2019
Last Update Posted:
Aug 30, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital Inselspital, Berne
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 30, 2021